Clinical trials: Pulmonary Hypertension
Hypertension, Pulmonary
The Effect of Tracleer® on Male Fertility
The objective of the study is to evaluate the effects of chronic TRACLEER® treatment on testicular function via semen analysis in male patients with primary pulmonary arterial hypertension (PAH).
- Trial name
- NCT00082186
- Testing
- bosentan
- Volunteers
- 22 people
- Sponsor
- Actelion
Hypertension, Pulmonary
Safety of Terbogrel in Patients With Primary Pulmonary Hypertension
Study to assess the safety of terbogrel during open-label, long-term treatment in medically stable or improving patients with primary pulmonary hypertension who have completed the 12-week, double-blind randomized trial of…
- Trial name
- NCT02223494
- Testing
- Terbogrel
- Volunteers
- 33 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Pulmonary
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial…
- Trial name
- AMBITION (NCT01178073)
- Testing
- ambrisentan, tadalafil
- Where
- 143 sites in United States, Australia and 12 more
- Volunteers
- 610 people
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
- Trial name
- LEVEL (NCT05983250)
- Testing
- TNX-103
- Where
- 42 sites in United States, Canada
- Volunteers
- 230 people
- Sponsor
- Tenax Therapeutics, Inc.
Interstitial Lung Disease, COPD
Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor lung that were preserved and transported within the LUNGguard system, as well as…
- Conditions
- Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- GUARDIANLUNG (NCT04930289)
- Testing
- LungGuard, BAROGuard
- Where
- 15 sites in United States, Belgium
- Volunteers
- 3,500 people
- Sponsor
- Paragonix Technologies
Vascular Disease
Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
This open label, single-arm, non-controlled, multicentre study will determine the effect of ambrisentan on exercise capacity (6MWT) in Chinese subjects with PAH.
- Trial name
- NCT01808313
- Testing
- ambrisentan
- Where
- 12 sites in China
- Volunteers
- 134 people
- Sponsor
- GlaxoSmithKline
Hypertension, Pulmonary
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.
- Trial name
- NCT00185315
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- 16 sites in Belgium, France and 5 more
- Volunteers
- 71 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Effect of Food on BIA 5-1058
The aim of this study is to investigate the effect of food on the pharmacokinetic (PK) profile of BIA 5-1058 after a single dose in healthy subjects.
- Trial name
- NCT04991155
- Testing
- BIA 5-1058
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Heart Defects, Congenital, Hypertension, Pulmonary
Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery
This clinical trial will determine the safety and effectiveness of intravenous L-citrulline in children undergoing cardiopulmonary bypass during heart surgery.
- Trial name
- NCT00335244
- Testing
- L-citrulline
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Asklepion Pharmaceuticals, LLC
Pulmonary Arterial Hypertension
Assessing the Utility of Submaximal CPET in Treatment Management of PAH
Pulmonary hypertension (PH) is associated with worsening breathlessness and exercise capacity, right-heart failure, and adverse outcomes including increased mortality.
- Trial name
- NCT05977933
- Testing
- Shape II CPET
- Where
- 6 sites in United States
- Volunteers
- 550 people
- Sponsor
- Shape Medical Systems, Inc.
Pulmonary Fibrosis, Pulmonary Hypertension
Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis
An expanded access program that provides INOpulse treatment to patients with serious disease or conditions associated with pulmonary hypertension associated with pulmonary fibrosis who are not able to participate in the Sponsor's…
- Trial name
- NCT05356052
- Testing
- INOpulse
- Sponsor
- Bellerophon
Pulmonary Arterial Hypertension
Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension
This study is a phase IIa proof-of-concept study to evaluate the effect of single-dose TPN171H tablets on acute haemodynamic parameters in patients with pulmonary arterial hypertension.The trial is expected to include 60…
- Trial name
- NCT04483115
- Testing
- TPN171H, Tadalafil
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- Vigonvita Life Sciences
Pulmonary Arterial Hypertension
Eisenmenger Quality Enhancement Research Initiative
Eisenmenger Quality Enhancement Research Initiative (QuERI) is a multi-center, observational, US-based longitudinal program, with enrollment of consecutive Eisenmenger patients who meet enrollment.
- Trial name
- ES-QuERI (NCT01623492)
- Testing
- Subjects with diagnosis of Eisenmenger Syndrome
- Volunteers
- 193 people
- Sponsor
- Actelion
Hypertension, Pulmonary
Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
The safety and efficacy at 100 mg once daily for oral dose of sitaxentan sodium were demonstrated in the STRIDE clinical trial program. Sitaxentan sodium was approved in the EU, Canada and Australia.
- Trial name
- NCT01210443
- Testing
- Sitaxentan
- Where
- 2 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Pfizer
Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
To evaluate the efficacy and safety of 26-weeks of treatment with riociguat vs. placebo in patients with symptomatic PH (pulmonary hypertension) associated with IIP (idiopathic interstitial pneumonias).
- Trial name
- RISE-IIP (NCT02138825)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 93 sites in United States, Argentina and 19 more
- Volunteers
- 147 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the…
- Trial name
- STRIDE-3 (NCT00811018)
- Testing
- Sitaxsentan
- Where
- 91 sites in United States, Argentina and 14 more
- Volunteers
- 1,192 people
- Sponsor
- Pfizer
Hypertension, Pulmonary
Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension
Local, prospective, multicenter, non-comparative, non-interventional, observational study. It is planed to assess compliance of patients with PH (pulmonary hypertension) with the physician's recommendation in real practice.
- Trial name
- IVENT (NCT01971450)
- Testing
- Iloprost (Ventavis, BAYQ6256)
- Where
- Russia
- Volunteers
- 89 people
- Sponsor
- Bayer
Healthy Volunteers, Pulmonary Arterial Hypertension
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
- Trial name
- NCT06649110
- Testing
- LTP
- Where
- 87 sites in United States, Argentina and 16 more
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide
This is an open label phase 2 pilot study designed to evaluate the safety, tolerability and device performance of the GeNO nitrosyl delivery system during right heart catheterization (RHC) in participants with pulmonary arterial…
- Trial name
- PILOT (NCT01092559)
- Testing
- Nitric Oxide generated by the GeNO nitrosyl delivery system
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Geno LLC
Pulmonary Hypertension, Pulmonary Fibrosis
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis
A phase 2b, open label study to assess the safety and efficacy of increasing doses of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis and sarcoidosis on long term oxygen therapy followed by a long term…
- Conditions
- Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
- Trial name
- NCT03727451
- Testing
- iNO
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bellerophon